STM JOURNALS

Research & Reviews: A Journal of
Drug Design & Discovery

ISSN: 2349-9036
Volume 12, Issue 3, 2025
September–December
DOI (Journal): 10.37591/RRJoDDD

https://journals.stmjournals.com/rrjoddd

Review RRJoDDD

Review on Atorvastatin as a Potent Drug for CVD

Usama Kasam Rinde[1,*], Sonali Dheeraj Parab[1], Aarya Abhijit Tanawade[1], Nikhil Mangesh Patil[2]

Abstract

Cardiovascular disease (CVD), particularly atherosclerosis, remains the leading cause of death worldwide, significantly burdening public health, especially in western societies. Metabolic syndrome and arrhythmic complications further exacerbate cardiovascular morbidity and mortality. Among restorative specialists, statins particularly atorvastatin have gotten to central in both the essential and auxiliary anticipation of coronary heart infection (CHD) due to their strong lipid-lowering properties and additional pleiotropic impacts. Atorvastatin, a selective HMG-CoA reductase inhibitor, not only reduces low-density lipoprotein cholesterol (LDL-C) by up to 60% but also improves endothelial function, decreases oxidative stress, and stabilizes atherosclerotic plaques. Long half-life and liver selectivity, advantageous pharmacokinetic profiles promote its effectiveness. Clinical studies, such as Ascot-LLa, TNT, and CARDs, have reduced the benefits of reducing important unwanted cardiovascular events, particularly in high-risk patients, including older adults. Despite some instances of statin intolerance, atorvastatin arraying a strong safety and efficacy record. With its broad cardiovascular benefits, cost-effectiveness, and growing role in personalized medicine, atorvastatin remains a cornerstone of modern cardiovascular risk management.

Keywords: Atherosclerotic plaque stabilization, cardiovascular disease (CVD), pleiotropic effects, acute coronary syndrome (ACS), atorvastatin-HMG-CoA reductase inhibitors, low-density lipoprotein (LDL-C) & high-density lipoprotein (HDL-C), clinical trials (ASCOT-LLA, TNT, CARDS)

INTRODUCTION TO CVD & HISTORY

Atherosclerosis is a major cause of about 50% of all deaths in a westernized society, and in many cases, the diagnosis of metabolic syndrome is a subject with atherosclerosis and cardiovascular disease. Adverse lifestyle factors are not associated with the progression of atherosclerosis, which results in severe cardiovascular diseases, complications, and mortality [1, 2].

Ventricular and atrial arrhythmias lead to severe morbidity, coma, and death. More than half of a patient with ischemic cardiovascular disease dies because of ventricular arrhythmia and ventricular tachyarrhythmia, the most common and severe heart dysplasia. With an estimated 84% of the total sudden cardiac mortality. Individuals with metabolic disorders have three times the chance of creating coronary heart malady, as well as much higher cardiovascular dismalness [3].

Cardiovascular disease (cardiovascular disease) is the main cause of death, which is about 30% of all deaths around the world. 3-hydroxy-3-methyl hydroxy-3-methyl glutaryl coenzyme-A (HMG-CoA) reductase inhibitors or agents that reduce lipids, such as “statin”, are widely used as a powerful pharmacological choice to reduce low density lipoprotein (LDL-C) cholesterol in blood [4].

***Author for Correspondence**
Usama Kasam Rinde
E-mail: rindeusama01@gmail.com

[1]Research Scholar, Department of Pharmacy, SSPM’s V. P. College of Pharmacy, Madkhol, Sawant Wadi, Maharashtra, India
[2]Assistant Professor, Department of Pharmacy, SVS’s Dadasaheb Rawal Pharmacy College, Dondaicha, DBATU University, Raigad, Lonere, Maharashtra, India

Received Date: August 01, 2025
Accepted Date: August 07, 2025
Published Date: August 26, 2025

Citation: Usama Kasam Rinde, Sonali Dheeraj Parab, Aarya Abhijit Tanawade, Nikhil Mangesh Patil. Review on Atorvastatin as a Potent Drug for CVD. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(3): 8–18p.

DRUG PROFILE OF ATORVASTATIN

Atorvastatin has been profoundly researched among older adults and has the most significant magnitude of beneficial effects on clinical outcomes of CHD. Atorvastatin has demonstrated that plaque's volume evolution gradually slowed down and improved plaque's overdose. Atorvastatin reduces endothelial dysfunction associated with atherosclerosis, and this impact is noticeable within 24 hours, before the effects on CRP and cholesterol become apparent. Statin can inhibit the inhibitory action of the endothelial nitrogen and increase its activity directly, which increases the bioavailability of nitrogen oxide (Figures 1–3 and Tables 1 and 2) [5, 6].



Figure 1. Structure of atorvastatin from Way2Drug.

STRUCTURE & CHEMISTRY

Atorvastatin has a distinct structure, a long half-life, and hepatic selectivity, which explains its more reliable LDL-lowering activity compared to other HMG-CoA. In addition, it has demonstrated that it activates numerous signal survival methods to reduce the size of heart attack and onset. Statin/Atorvastatin, a parent compound of (3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor) could be a sort of sedate utilized to treat hyperlipidemia in future. Atorvastatin is powerful according to the characteristics of the active inhibitors of the enzyme that likes 3-hydroxy-3-methylglutaryl, which limits the speed of enzymes in the production of cholesterol-de-nova. This suppression of enzymes last 20–30 hours and the removed half-life (14 hours) is longer than other statins except Rosuvastatin (19 hours) and the active metabolic products last much longer. The stereochemistry of the lactone rings, its ability to be hydrolyzed, and the length of the bridge linking the two ring systems all influence HMGRI activity. The hydrophobic ring core of statins, which extends beyond the HMG-CoA–mimetic moiety, engages in extensive van der Waals and π–stacking interactions with non-polar residues lining the HMG-CoA reductase active site. This hydrophobic tying down successfully ties the inhibitor inside the binding stash, subsequently lessening its relocation by the endogenous HMG-CoA substrate and improving competitive hindrance of the protein [5–9].



Figure 2. Structure of atorvastatin from mol-inspiration.



Figure 3. Structure of atorvastatin.

Table 1. Predicted biological activities of the compound based on probability scores (Pa = probability to be active; Pi = probability to be inactive).

Pa (Probability to Be Active)	Pi (Probability to Be Inactive)	Activity
0,860	0,005	Hypolipemic
0,561	0,028	Antianginal
0,545	0,018	APOA1 expression enhancer
0,511	0,020	Anti-hypercholesterolemic
0,467	0,005	Cholesterol synthesis inhibitor
0,218	0,121	Anti-ischemic
0,353	0,233	Anti-ischemic, cerebral
0,399	0,001	HMG-CoA reductase inhibitor (primary statin mechanism)
0,448	0,026	Atherosclerosis treatment
0,356	0,0014	Lipoprotein disorder treatment
0,366	0,041	Intermittent claudication (linked to peripheral disease)
0,271	0,204	Platelet derived growth factor receptor kinase inhibitor (vascular remodeling)
0,279	0,261	Platelet aggregation stimulant (could be pro-CVD depending on context)
0,110	0,098	Platelet antagonist (anti-thrombin)

Table 2. Physicochemical and molecular properties of atorvastatin.

IUPAC Name	**(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid**
Molecular formula	$C_{33}H_{35}FN_2O_5$
milLogP	5.43
TPSA (molecular polar surface area)	111.79
n atoms (number of atoms of molecule)	41
MW (molecular weight)	560.67
nON (hydrogen bond acceptor)	7
nOHNH (hydrogen bond donor)	4
n violation (molecule deviation through Lipinski rule of 5)	2
Nrotb (number of rotatable bonds)	12
Volume (molecular volume)	519.99

MECHANISM OF ACTION

Atorvastatin acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase, the rate-limiting chemical in hepatic cholesterol biosynthesis. By an official to the dynamic location, it decreases change (HMG-CoA) to mevalonate & bring down liver cholesterol which actuates up regulation of LDL receptor, improves LDL clearance & diminishes serum LDL-C, Apo B & triglyceride whereas assumingly expanding HDL-C by ~5–10%.

Past Lipid-Lowering, Atorvastatin Applies a Few Pleiotropic Cardiovascular Benefits

- *HDL Tweak & Antioxidant Improvement:* It unassumingly raises HDL-C and shifts HDL subpopulations towards bigger, more defensive forms, whereas upgrading HDL-associated proteins (paraoxonase-1, LCAT) and diminishing CETP movement.
- *Lipoprotein Oxidation Lessening:* In vitro and ex vivo considers illustrate that atorvastatin in portion by means of its hydroxylated metabolites reduces oxidation of LDL, HDL, and VLDL, diminishes oxidized LDL substance, and progresses endothelial work.
- *Endothelial and Anti-inflammatory Properties:* It constricts oxidative stretch by repressing Rac1/NADPH oxidase pathways and diminishes markers, like malondialdehyde, ADMA, and homocysteine, whereas expanding nitric oxide bioavailability.

Hypertension frequently coexists with dyslipidemia, both major chance components for coronary artery disease (CAD). Whereas antihypertensive medicines alone may not completely normalize cardiovascular mortality hazard, statin therapy especially when combined with CAD management significantly brings down cardiovascular morbidity and mortality over the total hazard spectrum. Atorvastatin is, hence demonstrated for essential and auxiliary avoidance of CAD, atherosclerosis, dyslipidemia, and related cardiovascular illnesses. Its multifaceted effects competitive HM-CoA reductase hindrance, LDL-C decrease, HDL-C upgrade, oxidative stretch relief, and endothelial stabilization collectively diminish the frequency of antagonistic cardiovascular events [9–13].

PHARMACOLOGY

Statins are a powerful inhibitor of cholesterol generation. They have risen as the foremost successful restorative lesson of lipid-lowering solutions, and they are utilized in both essential and auxiliary avoidance of coronary course illness. Statins were first discovered as secondary metabolites of fungus. ML-236B, one of the first natural inhibitors of HMG-CoA reductase, was isolated as a metabolite from Penicillium citrinum cultures and discovered to be an extraordinarily powerful competitive inhibitor of HMG CoA reductase. Statins bind to the active center of the enzyme to inhibit HMG COA, reduce the enzyme, and prevent transfer from substrate to product state. Each statin has a distinct tissue permeability and pharmacokinetic profile. Statins also have extra-hepatic effects because they inhibit the synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway, such

as farnesyl-pyrophosphate (FPP) and geranyl-geranyl pyrophosphate (GGPP), which are downstream from L-mevalonic acid (Figure 4) [9–10, 14–15].



Figure 4. Pharmacology of atorvastatin.

PHARMACOKINETICS

Atorvastatin is readily absorbed, with peak serum concentrations occurring within 1 to 2 hours. Atorvastatin has an absolute bioavailability of about 14%, and the possibility of the whole body is about 30% of the inhibitory effect of HMG COA. Atorvastatin is more than 98% of plasma protein. Active metabolites are responsible for approximately 70% of the circulatory inhibition of HMG-CoA reductase. In humans, intermediate plasma removal is the half-life of atorvastatin of approximately 14 hrs. Be that as it may, the half-life of inhibitory activity for HMG-CoA reductase is 20–30 hours, due to the inclusion of dynamic metabolites [9, 10].

TOLERANCE

Statin intolerance is characterized by the International Lipid Expert Panel as the failure to endure a statin measurement essential to decrease cardiovascular chance. It can moreover be characterized as not able to resist at slightest two statins or as not able to switch between three statins inside a year. Statins are related with a grouping of side impacts, of which the first common complaints of muscle complaints are the ones. Plain myalgia has the potential to be clinically significant, according to several investigations. The report on the frequency of statins associated with observation studies and muscle ships (SAM) is between 17% and 30%, and randomized contrast research (RCT) represents a much lower percentage (4.9%). STOMP is the only random, double blinds, and placebo-controlled study aimed at studying the effects of statins (80mg of atorvastatin) on the skeletal muscles in 420 statin objects received for six months. In general, 9.4% of patients are receiving atorvastatin and 4.6% with placebo ($p = 0.054$) [10, 16–17].

CLINICAL EVIDENCE

Several clinical trials have investigated the positive effects of statins in those who have or are at risk of developing CHD. Statin treatment has appeared in a few imminent randomized clinical trials. It considers to viably diminish the frequency of major coronary occasions in essential and auxiliary anticipation settings. Unfortunately, the early statin trials suffered from severe age and gender bias, since most of them recruited a limited number of women and the elderly, resulting in insufficient representation of that patient population. Studies show that statins are significantly underestimated in older patients, especially under secondary prevention conditions. This suspicion is advance bolstered

by information from the National Registry of Myocardial Localized necrosis 3 and the Worldwide Registry of Intense Coronary Occasions (GRACE) (Figures 5 and 6) [5, 18–20].

- Secondary anticipation ponders with atorvastatin positive benefits have been altogether inspected both in patients with steady CHD and in patients with later intense coronary events.
- Clinical objectives for intense coronary disorder (ACS), pravastatin or atorvastatin assessment and contamination treatment thrombolysis (certifying IT-TIMI) in myocardial infarction 22 trials assessed the impacts of standard (LDL-C 100 mg/dl) vs productivity (LDL-C 70 Mg/DL) 40 MG 40 MG 40 MG 40 MG/DL. MG/D of 4162 patients (730 patients 70 a long time old), ACS inside the past 10 days.
- Subsequent analysis of the comparison between a young patient and a patient between 65 and 75 years old shows that atorvastatin's treatment reduces 38% of RR reduction (95% CI –58 to –8, P = 0.017) of the first major cardiovascular event in older patients, as well as a reduction in 37% (95% CI –57) to –7, P = 0.09) (Table 3).



Figure 5. Clinical evidence of atorvastatin.



Figure 6. Graphical representation of atorvastatin in treatment of CVD.

CVD REGARDING ATORVASTATIN

Atorvastatin, a synthetic HMG-CoA reductase inhibitor, occupies a pivotal role in both the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), owing not only to its potent lipid-lowering capacity but also to its extensive pleiotropic properties. Through competitive

inhibition of the HMG-CoA reductase enzyme, atorvastatin significantly reduces intrahepatic cholesterol synthesis, leading to upregulation of LDL receptors and enhanced clearance of circulating low-density lipoprotein cholesterol (LDL-C), with dose-dependent reductions reaching up to 60%. However, the clinical use of lipid control is exceeded. Atorvastatin presents protective spectra of blood vessels, including weakening endothelial dysfunction, high sensitivity of C-reactive protein (HS-CRP), inhibition of vascular inflammation, stabilizing-atherosclerosis, oxidation, and stabilizing half-moon measurements. Important tests, such as ASCOT-LLA, Cards, and TNT, have stably proved the effects of Atorvastatin in reducing major side effects (MACE) by the spectrum of the group, including hypertension patients. In high -risk coaches, concentration therapy using 80 mg/day atorvastatin showed excellence in the prevention of recurrent ischemic events reflected in TNT and ideal studies. In addition, a new understanding of pharmaceutical genomics, especially SLCO1B1 genes, provides statin personalized treatment, minimizes the risk of muscle symptoms associated with statins, minimizes long-term growth. Coupled with a favorable cost-effectiveness profile due to its generic availability, atorvastatin remains a cornerstone in contemporary cardiovascular risk reduction strategies, aligning with global guideline recommendations for aggressive LDL-C lowering to achieve optimal vascular outcomes [21–29].

Table 3. Comparison of major clinical trials (PROVE-IT, IDEAL, and TNT) evaluating statin therapy: inclusion criteria, baseline characteristics, interventions, achieved LDL levels, and follow-up duration.

Clinical Trials	PROVE-IT	IDEAL	TNT
Patients	n = 4162	n = 8888	n = 10001
Included	• Age > 18 y • Clinically stable • Hospitalized for ACS in last 10 days • If PCI planned done • Total cholesterol < 6.2 mmol/L (already on lipid-lowering: <5.2 mmol/L)	• Age < 80 y • Hx of MI	• Age 35–75 y • Previous MI, history of angina with evidence of atherosclerosis CAD, prior CABG/PCI • LDL 3.4–6.5 mmol/L off lipid-lowering & <3.4 mmol/L on atorvastatin 10 mg/d
Baseline	• Age 58 y • Female 22% • 7 days from ACS • STEMI 33% • NSTEMI 37% • LDL 2.7 mmol/L	• Age 62 y • Female 19% • 1.8 y from MI • LDL 3.2 mmol/L • ASA 80%, ACEI 30%, ARB 6%, beta-blocker 75%	• Age 61 y • Female 19% • MI 58%, angina 82%, PCI 54%, CABG 46% • LDL 3.9 mmol/L
Intervention	Atorvastatin 80 mg/Day		
Control	Pravastatin 40–80 mg/Day	Simvastatin 20–40mg/Day	Atorvastatin 10mg/Day
Achieved-LDL (mmol/L)	1.6 vs. 2.5	2.1 vs. 2.7	2.0 vs. 2.6
Follow-up (median)	2 years	4.8 years	4.9 years

PLEIOTROPIC EFFECT

The name “pleiotropy” derives from the Greek words “pleio” (many) and “trepein” (influencing). Statin many bodies have been shown to have advantages by modulating many biological pathways involved in anti-inflammatory, immune modulation, and anticoagulants. Statins are now recognized to be useful in primary prevention, reducing all-cause mortality, cardiovascular illnesses, coronary heart disease, and stroke with no indication of substantial damage caused by their usage [14, 18, 30–31] (Figure 7).

Pharmacogenomics & Personalized Medicine

Variants in SLCO1B1 influence statin metabolism & risk of myopathy. Pharmacogenetic screening may guide personalized statin therapy, minimizing adverse effect while maintain efficacy [32].



Figure 7. Pleotropic effect of statin.

Cost-Effectiveness & Accessibility

As a generic medication, atorvastatin is widely available & cost effective. It is included in most clinical guidelines due to its affordability and evidence-based efficacy (Table 4) [33].

Table 4. Summary.

Category	Key Points
Mechanism	HMG-CoA Reductase inhibition
Lipid effect	Decrease LDL-C by up to 60%, Increase HDL-C by 5–10%
Pleiotropic Action	Improves endothelium, decreases inflammation, stabilizes plaques
Clinical Role	Proven in ASCOT-LLA, TNT, CARDS trials.
Tolerability	Generally safe; rare myopathy
Pharmacogenomics	SLCO1B1 polymorphisms guide dosing
Cost	Affordable, widely available generic

CONCLUSIONS

Atorvastatin, a potent HMG-CoA reductase inhibitor, plays a central role in the prevention and management of atherosclerotic cardiovascular disease (ASCVD). It effectively reduces LDL-C levels and provides significant protection against coronary heart disease, both primary and secondary prevention. Beyond its lipid-lowering action, atorvastatin exhibits several pleiotropic effects, including improving endothelial function, reducing vascular inflammation, stabilizing atherosclerotic plaques, and lowering high-sensitivity C-reactive protein levels.

Clinical studies, such as Ascot-LLa, TNT, and CARDs, have reduced the benefits of reducing important unwanted cardiovascular events, particularly in high-risk patients, including older adults. Despite some concerns over statin intolerance and myopathy, atorvastatin maintains a favorable safety profile and is cost-effective due to its widespread generic availability. Its long half-life, hepatic selectivity, and ability to influence genetic factors, like SLCO1B1, further enhance its clinical utility.

Altogether, atorvastatin remains a cornerstone in the global strategy for cardiovascular risk reduction, with its comprehensive benefits far exceeding cholesterol control alone.

Atorvastatin Overview

Lipid-Lowering Action

- *Mechanism*: Inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver.
- *Outcome*: Decreases LDL-C levels, a key risk factor for atherosclerosis.

Pleiotropic Effects

- *Endothelial Function*: Enhances nitric oxide (NO) production, improving blood vessel dilation.
- *Inflammation Reduction*: Lowers high-sensitivity C-reactive protein (hs-CRP) levels, indicating reduced vascular inflammation.
- *Plaque Stability*: Inhibits LDL oxidation and smooth muscle cell proliferation, stabilizing atherosclerotic plaques.
- *Antithrombotic Effects*: Reduces platelet aggregation and fibrinogen levels, decreasing clot formation risk.

Clinical Benefits

- *Primary Prevention*: Reduces the incidence of first heart attacks and strokes.
- *Secondary Prevention*: Decreases the risk of recurrent cardiovascular events in patients with existing heart disease.

Acknowledgment

The author & co-author sincerely acknowledged support and guidance provided by faculty of V. P. College of Pharmacy, Madkhol, Sawantwadi, DBATU University, Raigad, Lonere, during this review preparation. We are also grateful for collaborative efforts of authors & co-authors and the access to scientific literature that facilitated a comprehensive understanding of atorvastatin's role in cardiovascular disease management. The authors are also grateful towards several authors & journal publications that played key role indirectly by providing easy usability of raw data from article/journal. Thank You.

REFERENCES

1. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol. 1990 May 22;65(19):42–8.
2. Liptak B, Knezl V, Gasparova Z. Anti-arrhythmic and cardio-protective effects of atorvastatin and a potent pyridoindole derivative on isolated hearts from rats with metabolic syndrome. Bratisl Med J. 2019;120(3):200–6. doi:10.4149/BLL_2019_034.
3. Roy D, et al. Comparing effectiveness of high-dose atorvastatin and rosuvastatin among patients undergone percutaneous coronary interventions: A non-concurrent cohort study in India. PLoS One. 2020 May;15(5):e0233230. doi:10.1371/journal.pone.0233230.
4. Elmadbouh I, Mansour M, Nabeh M, Faried W, Abdelsabour A, Omar A. Atorvastatin improves cardiac function and remodeling in chronic non-ischemic heart failure: A clinical and pre-clinical study. Egypt Heart J. 2015 Dec;67(4):289–98. doi:10.1016/j.ehj.2014.11.003.
5. Acharjee S, Welty FK. Atorvastatin and cardiovascular risk in the elderly: Patient considerations. Clin Interv Aging. 2008;3(1):81–9. doi:10.2147/cia.s2442.
6. Godoy JC, et al. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J. 2019 Jan;33(1):1209–25. doi:10.1096/fj.201800876R.
7. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005 Sep;96(5 Suppl):24F–33F. doi:10.1016/j.amjcard.2005.06.009.
8. Sai C, Li J, Ruiyan M, Yingbin X. Atorvastatin prevents postoperative atrial fibrillation in patients undergoing cardiac surgery. Hellenic J Cardiol. 2019 Jan;60(1):40–7. doi:10.1016/j.hjc.2017.12.012.

9. Virani PA, Sojitra RA, Raj HA, Jain VI. A review on irbesartan co-administered with atorvastatin for the treatment of cardiac risk. J Crit Rev. 2014;1(1):25–8.
10. Raschi E, Casula M, Cicero AFG, Corsini A, Borghi C, Catapano A. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacol Ther. 2023 Oct;108507. doi:10.1016/j.pharmthera.2023.108507.
11. Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events. Korean Circ J. 2017 Jul;47(4):432–43. doi:10.4070/kcj.2016.0406.
12. Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol. 2016 Sep;105(9):783–90. doi:10.1007/s00392-016-0991-z.
13. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4(2):341–53. doi:10.2147/vhrm.s1653.
14. Zhou Q, Liao JK. Statins and cardiovascular diseases: From cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15(5):467–78.
15. Sawada N, Liao JK. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal. 2014 Mar;20(8):1251–67. doi:10.1089/ars.2013.5524.
16. Banach M, Mikhailidis DP. Statin intolerance: Some practical hints. Cardiol Clin. 2018 May;36(2):225–31. doi:10.1016/j.ccl.2017.12.004.
17. Parker BA, et al. Effect of statins on skeletal muscle function. Circulation. 2013 Jan;127(1):96–103. doi:10.1161/CIRCULATIONAHA.112.136101.
18. Bouillon K, et al. Association of statins for primary prevention of cardiovascular diseases with hospitalization for COVID-19: A nationwide matched population-based cohort study. J Am Heart Assoc. 2022 Jun;11(12):e023357. doi:10.1161/JAHA.121.023357.
19. Billings FT, et al. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: A randomized clinical trial. JAMA. 2016 Mar;315(9):877–88. doi:10.1001/jama.2016.0548.
20. Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: The clinical impact of atorvastatin. Curr Med Res Opin. 2008 Apr;24(4):1217–29. doi:10.1185/030079908X292001.
21. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol. 2013 Oct 15;168(6):5126–34. doi:10.1016/j.ijcard.2013.07.113.
22. Tonelli M, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. CMAJ. 2011 Nov;183(16):E1189–202. doi:10.1503/cmaj.101280.
23. Murphy WA, et al. Pharmacogenomic study of statin-associated muscle symptoms in the ODYSSEY OUTCOMES trial. Circ Genom Precis Med. 2022 Jun;15(3):e003503. doi:10.1161/CIRCGEN.121.003503.
24. Singh V, Deedwania P. Reducing morbidity and mortality in high-risk patients with statins. Vasc Health Risk Manag. 2009;5:617–28. Available from: https://www.dovepress.com.
25. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007 Feb;28(2):88–98. doi:10.1016/j.it.2006.12.003.
26. Sever PS, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care. 2005;28(5):1151–7. Available from: https://www.ascotstudy.org.
27. Opie LH, Dalby AJ. Cardiovascular prevention: Lifestyle and statins – competitors or companions? S Afr Med J. 2014;104(3):168–73. doi:10.7196/SAMJ.7942.
28. Taylor F, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816. doi:10.1002/14651858.CD004816.pub5.
29. Yamamuro S, Shinozaki T, Iimuro S, Matsuyama Y. Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin's effect on

cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Stat Methods Med Res. 2021 Aug;30(8):1782–99. doi:10.1177/09622802211025988.
30. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004 Jun 15;109(23 Suppl 1):III39–43. doi:10.1161/01.CIR.0000131517.20177.5a.
31. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017 Jan 6;120(1):229–43. doi:10.1161/CIRCRESAHA.116.308537.
32. Link E, et al. SLCO1B1 variants and statin-induced myopathy: A genomewide study. N Engl J Med. 2008 Aug 21;359(8):789–99. doi:10.1056/NEJMoa0801936.
33. Loch A, Bewersdorf JP, Kofink D, Ismail D, Abidin IZ, Veriah RS. Generic atorvastatin is as effective as the brand-name drug (Lipitor®) in lowering cholesterol levels: A cross-sectional retrospective cohort study. BMC Res Notes. 2017 Jul;10(1):306. doi:10.1186/s13104-017-2617-6.

